Overview
PathAI is a technology company focused on AI-driven pathology analysis, dedicated to improving patient diagnosis and treatment outcomes through reliable artificial intelligence technology. Its core product, the AISight digital pathology platform, has obtained FDA 510(k) clearance and CE-IVDR certification, providing pathology laboratories and biopharmaceutical companies with a full-process solution from tissue slide digitization to AI-assisted diagnosis. In 2025, Roche acquired PathAI for $750 million, further advancing the clinical translation of AI pathology diagnosis.
Key Features
- AISight Digital Pathology Platform: Offers two systems: AISight Image Management System (RUO) and AISight Dx (FDA/CE certified), supporting digital management of pathology slides, remote consultation, and AI analysis, compatible with multiple scanner formats.
- AI Companion Diagnostic Algorithms: Includes AIM series algorithms (e.g., AIM-PDL1, AIM-HER, AIM-ER, AIM-PR, AIM-Ki67) and METPredict, enabling automated assessment of biomarker expression to aid drug development and precision treatment decisions.
- Pathology AI Product Suite: Provides specialized algorithms such as ArtifactDetect (artifact detection), TumorDetect (tumor detection), AIM-Tumor Cellularity (tumor cellularity analysis), and PathAssistDerm (dermatopathology assistance).
- Third-Party Algorithm Integration: Supports integration of AI algorithms from partners like DeepBio, Paige, Visopharm, and DoMore Diagnostics to expand pathology analysis capabilities.
- Biopharmaceutical R&D Support: Offers translational research, clinical trial development, real-world data, and companion diagnostic services for biopharmaceutical companies, accelerating the transition of drugs from lab to clinic.
- Precision Pathology Network: Connects pathology laboratories and pharmaceutical companies through the Precision Pathology Network, enabling standardized data sharing and collaborative analysis.
Use Cases
- Digital transformation and AI-assisted diagnosis in pathology laboratories
- Biomarker analysis in drug development for biopharmaceutical companies
- Tumor detection and cellularity assessment in cancer diagnosis
- Companion diagnostic kit development and clinical trial support
Pros
- Obtained FDA 510(k) and CE-IVDR dual certifications, ensuring high clinical compliance
- After acquisition by Roche, has strong resource support and commercialization channels
- Algorithms cover multiple cancer types and key biomarkers, with wide application scenarios
- Supports third-party algorithm integration, offering strong platform openness
- Full-chain services from R&D to clinical application, suitable for collaboration between pharmaceutical companies and laboratories
Pricing
PathAI adopts a paid model; specific pricing needs to be obtained by contacting the sales team, with customized quotes based on usage scale (e.g., number of slides, algorithm modules, platform deployment method).
Summary
PathAI is suitable for clinical laboratories and biopharmaceutical companies requiring highly compliant AI pathology diagnosis. Its core advantages lie in the FDA/CE-certified AISight platform, a rich library of AI algorithms (covering tumor detection, biomarker analysis, etc.), and the industrial integration capabilities following the Roche acquisition. For institutions seeking precision pathology analysis and improved drug development efficiency, PathAI provides a one-stop solution from digitization to AI-assisted decision-making.